A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

International Clinical Psychopharmacology

Volumn 27, Issue 4, 2012, Pages 215-223

  Katona, Cornelius ^a   Hansen, Thomas ^b   Olsen, Christina Kurre ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b H LUNDBECK A S   (Denmark)

Author keywords

duloxetine, elderly; Hamilton Depression Scale; Lu AA21004; major depressive disorder; Montgomery sberg Depression Rating Scale; multimodal

Indexed keywords

ACETYLSALICYLIC ACID; DULOXETINE; HYDROCHLOROTHIAZIDE; MULTIVITAMIN; PLACEBO; SIMVASTATIN; VORTIOXETINE;

AGED; ARTICLE; COGNITION; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; HYPERHIDROSIS; LEARNING; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEMORY; MULTICENTER STUDY; NAUSEA; ORGASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PIPERAZINES; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SULFIDES; THIOPHENES;

EID: 84862132965     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283542457     Document Type: Article

References (31)

1. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F (2011). A double-blind, randomized, placebo-controlled, active-reference study of Lu AA21004 in patients with major depressive disorder (MDD). Int J Neuropsychopharmacol. doi: 10.1017/S1461145711001027.
2. American Psychiatric Association (APA) (2000). Diagnostic and statistical manual of mental disorders. Text revision (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Association.
3. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, et al. (2011). Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl] piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 54:3206-3221.
4. Beekman AT, Copeland JR, Prince MJ (1999). Review of community prevalence of depression in later life. Br J Psychiatry 174:307-311. (Pubitemid 29179713)
5. Boulenger JP, Loft H, Florea I (2012). A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. doi: 10.1177/0269881112441866.
6. Burt DB, Zembar MJ, Niederehe G (1995). Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychol Bull 117:285-305.
7. Cohen J (1988). Statistical power analysis for the behavioral sciences. New York: Erlbaum.
8. Ditlevsen S, Christensen U, Lynch J, Damsgaard MT, Keiding N (2005). The mediation proportion: a structural equation approach for estimating the proportion of exposure effect on outcome explained by an intermediate variable. Epidemiology 16:114-120. (Pubitemid 40239286)
9. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psych Res 12:189-198.
10. Gotlib IH, Joormann J (2010). Cognition and depression: current status and future directions. Annu Rev Clin Psychol 6:285-312.
11. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. Revised ed. Rockville, MD: National Institute of Mental Health.
12. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychology 32:50-55.
13. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
14. ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice (1996). Available at: http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm073122.pdf [Accessed 22 December 2011].
15. Kasper S, de Swart H, Andersen HF (2005). Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 13: 884-891. (Pubitemid 46638677)
16. Laughren T (2006). Food and Drug Administration, Center for Drug Evaluation and Research. Memorandum on Suicidality. 16 November 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-fda.pdf [Accessed 12 April 2012].
17. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. (1997). The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12:224-231. (Pubitemid 27298915)
18. Lezak MD (1983). Neuropsychological assessments. 2nd ed. New York: Oxford University Press.
19. Lladó-Pelfort L, Santana N, Ghisi V, Artigas F, Celada P (2011). 5-HT1A Receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb Cortex. doi: 10.1093/cercor/bhr220.
20. Montgomery S, A ° sberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. (Pubitemid 9136500)
21. Mørk A, Montezinho LC, Hovelsø N, Karlsson JJ, Murphy CT, Plath N, et al. (2011). Lu AA21004, a novel antidepressant, modulates neurotransmitter levels and theta oscillations, and exerts pro-cognitive effects in rats. Eur Neuropsychopharmacol 21 (Suppl 3):S407-S408.
22. Nelson JC, Delucchi K, Schneider LS (2008). Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 16:558-567.
23. Puig MV, Santana N, Celada P, Mengod G, Artigas F (2004). In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb Cortex 14:1365-1375. (Pubitemid 39507287)
24. Raskin J,Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, et al. (2007). Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164:900-909. (Pubitemid 46972905)
25. Rey A (1964). Clinical tests in psychology. Paris: Presses Universitaires de France.
26. Schatzberg A, Roose S (2006). A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 14:361-370.
27. Thomas AJ, Gallagher P, Robinson LJ, Porter RJ, Young AH, Ferrier IN, et al. (2009). A comparison of neurocognitive impairment in younger and older adults with major depression. Psychol Med 39:725-733.
28. Unü tzer J, Katon W, Callahan CM, Williams JW Jr, Hunkeler E, Harpole L, et al. 2003, Depression treatment in a sample of 1,801 depressed older adults in primary care. J Am Geriatr Soc, 51, 505-514. (Pubitemid 36457349)
29. Wechsler D (1997). Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, TX: Psychological Corporation.
30. Williams JB (2001). Standardizing the Hamilton Depression Rating Scale: past, present, and future. Eur Arch Psychiatry Clin Neurosci 251 (Suppl 2):II6-12.
31. World Medical Association (WMA)(2008). Declaration of Helsinki: ethical principles for medical research involving human subjects. World Medical Association (WMA);Available at:http://www.wma.net/en/30publications/1policies/ b3/index.html.pdf [Accessed 12 April 2012].